Vesicular monoamine transporter 1

From WikiMD's Medical Encyclopedia

Revision as of 11:47, 22 March 2024 by Prab (talk | contribs) (CSV import)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Vesicular monoamine transporter 1 (VMAT1) is a protein that in humans is encoded by the SLC18A1 gene. VMAT1 is a member of the solute carrier family and plays a critical role in the transport of monoamine neurotransmitters across the vesicular membranes within the central and peripheral nervous systems. This transport is essential for the storage of monoamines in synaptic vesicles, thereby regulating their availability for release and subsequent neurotransmission.

Function

VMAT1 functions by transporting monoamines—specifically serotonin, dopamine, norepinephrine, and histamine—from the cytosol into synaptic vesicles. This process is driven by a proton gradient across the vesicular membrane, which is generated by a vesicular ATPase. By sequestering monoamines into vesicles, VMAT1 plays a crucial role in controlling the strength and duration of monoamine signal transmission across synapses. This has significant implications for various physiological processes, including mood regulation, alertness, and the stress response.

Clinical Significance

Alterations in VMAT1 expression or function have been implicated in several neurological and psychiatric disorders. For example, reduced VMAT1 function can lead to decreased monoamine storage and, consequently, diminished neurotransmitter release into the synaptic cleft. This mechanism has been suggested to contribute to the pathophysiology of conditions such as depression, schizophrenia, and Parkinson's disease. Furthermore, VMAT1 is a target for various pharmacological agents, including reserpine, a drug that depletes monoamine stores by inhibiting VMAT1, thereby reducing neurotransmitter availability.

Genetic Aspects

The SLC18A1 gene, located on chromosome 8p21.3, encodes the VMAT1 protein. Genetic variations in SLC18A1 have been studied for their potential association with susceptibility to psychiatric disorders and response to psychotropic medications. However, the results of these studies have been mixed, indicating the need for further research to clarify the role of VMAT1 genetic variability in human health and disease.

See Also

References

<references/>

Template:Neurotransmitter metabolism

Stub icon
   This article is a medical stub. You can help WikiMD by expanding it!



Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.